Objective:
To evaluate the safety and efficacy of Ocugen's OCU410 gene therapy for geographic atrophy (GA) in a phase 1/2 study.
Key Findings:
- 23% slower GA lesion growth in the study eye compared to fellow eyes at 12 months in phase 1, with no serious adverse events reported.
- Phase 2 interim results showed 27% slower GA lesion growth compared to fellow eyes.
- Visual function improvement or stabilization of 2 lines in the study eye compared to fellow eyes.
Interpretation:
OCU410 demonstrates potential for slowing GA progression and improving visual function, with a favorable safety profile, including no serious adverse events.
Limitations:
- Small sample size in phase 1 and 2 studies.
- Short follow-up duration for assessing long-term efficacy.
- Typical procedure-related side effects were observed.
Conclusion:
OCU410 shows promise as a multi-mechanism gene therapy for GA, warranting further investigation in phase 3 trials planned for April 2026.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
